Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity.

Three slow-release preparations of theophylline have received approval from the U.S. Food and Drug Administration (FDA) for "once-daily" dosing indications, amid controversy regarding the appropriateness of this decision. Because of specific concerns regarding data submitted to the FDA in support of the first of these products to be approved, Theo-24, we examined the absorption characteristics of this newly marketed formulation. Eight healthy volunteers received, in a crossover manner, single doses of a theophylline reference solution and Theo-24, taken both fasting and after a breakfast of bacon and eggs. The concentrations of theophylline were measured up to 60 hours after the dose. Absorption of Theo-24 after an overnight fast was very slow, with only 71 +/- 6 percent (mean +/- SE) of the dose ultimately absorbed. In contrast, food caused precipitous "dose-dumping," resulting in dose-normalized peak levels in the serum that averaged 2.3 times higher than after a fasting dose. About half of the dose was absorbed in a four-hour period, generally beginning six to eight hours after the postprandial dose, and complete absorption was then attained within 24 hours (p less than 0.001). Toxic effects of theophylline occurred in four subjects when they took the dose with food whereas no toxic effects occurred during the fasting regimen. Consequently, doses of Theo-24 that would have attained a predicted peak concentration of 15 micrograms/ml after multiple dosing taken without food would, if taken with food, have resulted in larger fluctuations and in peak concentrations in the potentially toxic range for six of the eight subjects.

[1]  M. Weinberger,et al.  Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. , 1974, The Journal of pediatrics.

[2]  M. Weinberger,et al.  Dose-dependent kinetics of theophylline disposition in asthmatic children. , 1977, The Journal of pediatrics.

[3]  R. Schwartz Children with chronic asthma: care by the generalist and the specialist. , 1984, Pediatric clinics of North America.

[4]  L. Hendeles,et al.  A Clinical and Pharmacokinetic Basis for the Selection and Use of Slow Release Theophylline Products , 1984, Clinical pharmacokinetics.

[5]  L. Hendeles,et al.  Absolute bioavailability of oral theophylline. , 1977, American journal of hospital pharmacy.

[6]  P. Gal,et al.  Effect of Food on the Bioavailability and Pattern of Release of a Sustained‐Release Theophylline Tablet , 1982, Journal of clinical pharmacology.

[7]  L. Hendeles,et al.  Dose-dependent kinetics for theophylline: observations among ambulatory asthmatic children. , 1980, The Journal of pediatrics.

[8]  R. A. Zeeuw,et al.  A new in vitro dissolution test for controlled-release theophylline tablets , 1981 .

[9]  G. Milavetz,et al.  Dose Dependency for Absorption and Elimination Rates of Theophylline Implications for Studies of Bioavailability , 1984, Pharmacotherapy.

[10]  L Hendeles,et al.  Theophylline A “State of the Art” Review , 1983, Pharmacotherapy.

[11]  S. Pedersen,et al.  Influence of Food on the Absorption Rate and Bioavailability of a Sustained Release Theophylline Preparation , 1982, Allergy.

[12]  M. Weinberger Theophylline QID, TID, BID and Now QD? , 1984 .

[13]  R. Senior,et al.  Clinical experience with theophylline. Relarionships between dosage, serum concentration, and toxicity. , 1976, JAMA.

[14]  P. Lietman Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma , 1981 .

[15]  L. Hendeles,et al.  The relation of product formulation to absorption of oral theophylline. , 1978, The New England journal of medicine.

[16]  S. Pedersen,et al.  Erratic absorption of a slow-release theophylline sprinkle product. , 1984, Pediatrics.

[17]  P. Thompson,et al.  Slow release theophylline in patients with airways obstruction with particular reference to the effects of food upon serum levels. , 1983, British journal of diseases of the chest.

[18]  P. Welling,et al.  Influence of diet and fluid on bioavailability of theophylline , 1975, Clinical pharmacology and therapeutics.

[19]  K. Simons,et al.  Sustained-release theophylline for treatment of asthma in preschool children. , 1982, American journal of diseases of children.

[20]  M. Weinberger,et al.  Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn. , 1977, Pediatrics.

[21]  P. Welling,et al.  Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects. , 1983, Biopharmaceutics & drug disposition.

[22]  L. Hendeles,et al.  Current concepts. Slow-release theophylline rationale and basis for product selection. , 1983, The New England journal of medicine.

[23]  D. Nicholson Clinical experience with theophylline. , 1976, JAMA.

[24]  R. Matthay,et al.  Theophylline-induced seizures in adults. Correlation with serum concentrations. , 1975, Annals of internal medicine.

[25]  S. Pedersen,et al.  Influence of food on the absorption of theophylline from a sustained release formulation (Somophyllin ® ) , 1985, Clinical allergy.

[26]  J. Dasta,et al.  Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease. , 1979, American journal of hospital pharmacy.

[27]  M. Mathieu,et al.  Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: Influence of erythromycin , 1982, Clinical pharmacology and therapeutics.

[28]  W. H. Barr The Once‐Daily Theophylline Controversy , 1984, Pharmacotherapy.

[29]  M. Weinberger,et al.  Relationship of theophylline clearance to oral dosage in children with chronic asthma. , 1977, The Journal of pediatrics.